Brind.

Tango Therapeutics Shares Fall After Presenting Pancreatic Cancer Drug Results

1 report, 1 independent Updated Oct 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Tango Therapeutics presented updated results for its pancreatic cancer drug combination at the European Society for Medical Oncology Congress in Madrid on October 1, 2026. Following the presentation, Tango Therapeutics shares fell more than 16% in early trading, dropping to $23.40. The study, which tested the drug combination in previously treated patients, showed that 18 of 22 patients saw their tumors shrink, achieving an 82% response rate.

From ibtimes.com.au

Why it matters

Some supportBrind's analysis of the reports

The presentation of the clinical trial results for the combination drug vopimetostat and daraxonrasib is significant for the pancreatic cancer treatment industry. The market reacted negatively to the news, causing a sharp decline in Tango Therapeutics' stock price despite the high response rates reported in the study.

From ibtimes.com.au

Who's involved

  • Pancreatic Cancer Action NetworkNon-profit organization that supported the research presentation.
  • Lisa GrayServed as SVP for Development at Pancreatic Cancer Action Network.
  • PlanoCity where Pancreatic Cancer Action Network is situated.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped